CD47 and anemia: However, single‐agent treatment with CD47‐SIRPα blocking therapeutics in patients is associated with a lack of therapeutic effect at the maximum tolerated dose (MTD) and significant dose‐limiting toxicity (DLT), most notably anaemia and thrombocytopenia.12, 13, 14